IN LAS VEGAS IN JULY. SACRAMENTO KINGS ARE ON A BREAK UNTIL THIS FALL, BUT SOME PEOPLE SPOTTED THIS OVERNIGHT IN FOLSOM. VIEWER MATTHEW SALAZAR SAYS HE SAW A BRIGHT BLUE LIGHT FROM HIS BACKYARD IN ...
It has been about a month since the last earnings report for Beam Therapeutics Inc. (BEAM). Shares have added about 15.9% in that time frame, outperforming the S&P 500. But investors have to be ...
Beam Therapeutics BEAM announced that the FDA has granted an orphan drug designation to its investigational genome-editing candidate, BEAM-101, for the treatment of sickle cell disease (SCD), an ...
Eli Lilly & Co. is buying rights from Beam Therapeutics Inc. to develop and sell treatments for heart disease that make use of an experimental gene-editing technology. Lilly will pay Beam $200 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results